Following the identification of high NaPi2b expression (83% tumor proportion score), she initiated YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) utilizing a topoisomerase I inhibitor payload, at 2.0 mg/kg every 3 weeks.<h4>Results</h4>The patient achieved a sustained complete radiological response (CR) and CA-125 normalization 3.5U/ml after 24 weeks, remaining stable through 48 weeks treatment. This evidence concerns the gene SLC34A2 and neoplasm.